Progesterone regulation of activating protein-1 transcriptional activity: A possible mechanism of progesterone inhibition of endometrial cancer cell growth

Journal of Steroid Biochemistry and Molecular Biology

Volumn 87, Issue 2-3, 2003, Pages 123-131

  Dai, Donghai ^a   Litman, Elizabeth S ^a   Schonteich, Eric ^b   Leslie, Kimberly K ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Activating protein 1; c Fos; c Jun; Chromatin immunoprecipitation; Endometrial cancer; FosB; Fra 1; Fra 2; JunB; JunD; Progesterone; Progesterone receptors

Indexed keywords

CYCLIN D1; DNA; LIGAND; PROGESTERONE; PROGESTERONE RECEPTOR B; PROTEIN C JUN; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR AP 1;

ARTICLE; CANCER GROWTH; CELL STRAIN; CHROMATIN; CONTROLLED STUDY; DNA BINDING; ENDOMETRIUM CARCINOMA; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE TARGETING; HORMONAL REGULATION; HORMONE INHIBITION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PROMOTER REGION; PROTEIN FAMILY; PROTEIN FUNCTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0346219402     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2003.08.004     Document Type: Article

References (35)

1. Graham J.D., Clarke C.L. Physiological action of progesterone in target tissues. Endocr. Rev. 18:1997;502-519.
2. American Cancer Society, Cancer Facts and Figures, 2002.
3. Rose P.G. Endometrial carcinoma. N. Engl. J. Med. 335:1996;640-649.
4. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63:1994;451-486.
5. Conneely O.M., Lydon J.P. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids. 65:2000;571-577.
6. Lydon J.P., DeMayo F.J., Funk C.R., Mani S.K., Hughes A.R., Montgomery C.A. Jr., Shyamala G., Conneely O.M., O'Malley B.W. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev. 9:1995;2266-2278.
7. Shyamala G., Yang X., Silberstein G., Barcellos-Hoff M.H., Dale E. Transgenic mice carrying an imbalance in the native ratio of A to B forms of progesterone receptor exhibit developmental abnormalities in mammary glands. Proc. Natl. Acad. Sci. U.S.A. 95:1998;696-701.
8. Shyamala G., Yang X., Cardiff R.D., Dale E. Impact of progesterone receptor on cell-fate decisions during mammary gland development (in process citation). Proc. Natl. Acad. Sci. U.S.A. 97:2000;3044-3049.
9. Punnonen R., Mattila J., Kuoppala T., Koivula T. DNA ploidy, cell proliferation and steroid hormone receptors in endometrial hyperplasia and early adenocarcinoma. J. Cancer Res. Clin. Oncol. 119:1993;426-429.
10. Dai D., Wolf D.M., Litman E.S., White M.J., Leslie K.K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res. 62:2002;881-886.
11. Groshong S.D., Owen G.I., Grimison B., Schauer I.E., Todd M.C., Langan T.A., Sclafani R.A., Lange C.A., Horwitz K.B. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27 (Kip1). Mol. Endocrinol. 11:1997;1593-1607.
12. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr. Opin. Cell Biol. 9:1997;240-246.
13. Wisdom R. AP-1: one switch for many signals. Exp. Cell Res. 253:1999;180-185.
14. Angel P., Imagawa M., Chiu R., Stein B., Imbra R.J., Rahmsdorf H.J., Jonat C., Herrlich P., Karin M. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. 49:1987;729-739.
15. Deng T., Karin M. JunB differs from c-Jun in its DNA-binding and dimerization domains, and represses c-Jun by formation of inactive heterodimers. Genes Dev. 7:1993;479-490.
16. Szabowski A., Maas-Szabowski N., Andrecht S., Kolbus A., Schorpp-Kistner M., Fusenig N.E., Angel P. c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell. 103:2000;745-755.
17. Jacobs-Helber S.M., Wickrema A., Birrer M.J., Sawyer S.T. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol. Cell Biol. 18:1998;3699-3707.
18. Chiu R., Angel P., Karin M. Jun-B differs in its biological properties from and is a negative regulator of, c-Jun. Cell. 59:1989;979-986.
19. Fu S., Bottoli I., Goller M., Vogt P.K. Heparin-binding epidermal growth factor-like growth factor, a v-Jun target gene, induces oncogenic transformation. Proc. Natl. Acad. Sci. U.S.A. 96:1999;5716-5721.
20. Grigoriadis A.E., Schellander K., Wang Z.Q., Wagner E.F. Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol. 122:1993;685-701.
21. Philips A., Teyssier C., Galtier F., Rivier-Covas C., Rey J.M., Rochefort H., Chalbos D. FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol. Endocrinol. 12:1998;973-985.
22. Huang C., Ma W.Y., Dawson M.I., Rincon M., Flavell R.A., Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5826-5830.
23. Dai D., Kumar N.S., Wolf D.M., Leslie K.K. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. Am. J. Obstet. Gynecol. 184:2001;790-797.
24. Kumar N.S., Richer J., Owen G., Litman E., Horwitz K.B., Leslie K.K. Selective down-regulation of progesterone receptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action. Cancer Res. 58:1998;1860-1865.
25. Lambert J.R., Nordeen S.K. Analysis of steroid hormone-induced histone acetylation by chromatin immunoprecipitation assay. Methods Mol. Biol. 176:2001;273-281.
26. Brown P.H., Alani R., Preis L.H., Szabo E., Birrer M.J. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene. 8:1993;877-886.
27. Liu G., Chen N., Kaji A., Bode A.M., Ryan C.A., Dong Z. Proteinase inhibitors I and II from potatoes block UVB-induced AP-1 activity by regulating the AP-1 protein compositional patterns in JB6 cells. Proc. Natl. Acad. Sci. U.S.A. 98:2001;5786-5791.
28. Bos T.J., Margiotta P., Bush L., Wasilenko W. Enhanced cell motility and invasion of chicken embryo fibroblasts in response to Jun over-expression. Int. J. Cancer. 81:1999;404-410.
29. Young M.R., Li J.J., Rincon M., Flavell R.A., Sathyanarayana B.K., Hunziker R., Colburn N. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc. Natl. Acad. Sci. U.S.A. 96:1999;9827-9832.
30. Dong Z., Birrer M.J., Watts R.G., Matrisian L.M., Colburn N.H. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc. Natl. Acad. Sci. U.S.A. 91:1994;609-613.
31. Bakiri L., Lallemand D., Bossy-Wetzel E., Yaniv M. Cell cycle-dependent variations in c-Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 19:2000;2056-2068.
32. Alkhalaf M., Murphy L.J., Murphy L.C. Enhanced c-jun activity alters responsiveness to medroxyprogesterone acetate in Ishikawa human endometrial carcinoma cells. Mol. Endocrinol. 7:1993;1634-1641.
33. Sharma S.C., Richards J.S. Regulation of AP1 (Jun/Fos) factor expression and activation in ovarian granulosa cells. Relation of JunD and fra2 to terminal differentiation (in process citation). J. Biol. Chem. 275:2000;33718-33728.
34. Wardell S.E., Boonyaratanakornkit V., Adelman J.S., Aronheim A., Edwards D.P. Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. Mol. Cell Biol. 22:2002;5451-5466.
35. Lange C.A., Richer J.K., Horwitz K.B. Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol. Endocrinol. 13:1999;829-836.